| Name | Title | Contact Details |
|---|---|---|
Tony Cheng |
Chief Data and Information Officer | Profile |
Jeremy Landis |
Chief Technology Officer | Profile |
Brickhouse Martin Healthcare Engineering is a Centreville, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alquest has supported numerous international trials and registrations for device clients. Alquest's consulting staff comes from the medical device industry. We've been there. More than half our clients return to us for repeat business. Several device
Lawrence Community Health Svc is a Tuckahoe, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AGS Health is an analytics-driven, technology-enabled revenue cycle management company serving leading healthcare providers across the U.S. AGS Health partners with clients to tackle RCM data challenges; advising them on what questions to ask and helping them find answers.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.